Fibroblast growth factor 21 (FGF21) treatment drives metabolic improvements, including increased metabolic flux and reduced hepatic steatosis, but the mechanisms responsible for these effects remain to be elucidated fully. We tested whether a targeted reduction in hepatic peroxisome proliferator-activated receptor coactivator-1 (PGC-1 ), which has been shown to occur with obesity, had a negative impact on the metabolic effects of FGF21. We infused FGF21
INTRODUCTION
Fibroblast growth factor 21 (FGF21) is an endocrine hormone that is produced by the liver (Markan et al., 2014) and is upregulated in response to fasting or changes in macronutrient intake and as an acute response to exercise (Galman et al., 2008; Kim et al., 2013 von Holstein-Rathlou et al., 2016; Wasserman, Spalding, Bracy, Lacy, & Cherrington, 1989) . FGF21 is a powerful metabolic regulator that is capable of upregulating hepatic fatty acid oxidation (FAO), ketogenesis, gluconeogenesis and oxidative phosphorylation (Potthoff et al., 2009 ). FGF21 may potentially regulate these metabolic processes chronically through the modulation of gene transcription of specific metabolic proteins. Indeed, knocking down FGF21 results in a failure to upregulate genes associated with hepatic -oxidation in response to a ketogenic diet (Badman et al., 2007) . Conversely, acute FGF21 administration results in elevated transcription of the hepatic gluconeogenic enzymes glucose 6-phosphatase (G6Pase) and phosphoenol pyruvate carboxykinase (PEPCK; Fisher et al., 2011; Liang et al., 2014) , as well as 3-hydroxybutyrate dehydrogenase 1, an enzyme involved in ketogenesis (Fisher et al., 2011) . Chronic administration (8 days) of FGF21 has been shown to increase hepatic carnitine palmitoyl transferase alpha and beta (CPT1 and CPT1 ) and AMP activated protein kinase (AMPK 1) gene expression in ob/ob mice (Berglund et al., 2009) . Ultimately, through modulation of metabolism, FGF21 reduces adiposity and body weight, lowers circulating lipids and glucose, and abates hepatic steatosis (Coskun et al., 2008; Emanuelli et al., 2014; Holland et al., 2013; Veniant et al., 2012) .
Peroxisome proliferator-activated receptor coactivator protein-1 (PGC-1 ) is a transcriptional coactivator that plays a primary role in modulating mitochondrial biogenesis and overall oxidative capacity (Adhihetty et al., 2009; Wu et al., 1999) . Loss-of-function studies demonstrate that in the absence of PGC-1 , gluconeogenesis and -oxidation are significantly reduced, and these reductions may be attributable to the secondary effects of reductions in oxidative phosphorylation and the tricarboxylic acid cycle and overall metabolic dysfunction (Burgess et al., 2006) . Furthermore, liver-specific PGC-1 heterozygous mice were found to display greater hepatic steatosis in response to fasting, elevated circulating triglycerides, lower expression of genes involved in the oxidation of fatty acids, and disrupted hepatic insulin signalling (Estall et al., 2009 ). Similar to FGF21, hepatic PGC-1 is activated during exercise and times of fasting (Haase et al., 2011; Herzig et al., 2001; Norheim et al., 2014) and is crucial for both enhanced FAO and gluconeogenesis (Burgess et al., 2006; Morris et al., 2012) . Furthermore, FGF21 overexpression upregulates PGC-1 mRNA expression, whereas knocking out FGF21 reduces PGC-1 mRNA expression (Potthoff et al., 2009) . Previous research suggests that PGC-1 is reduced ∼50% in multiple tissues, including the liver, of insulin-resistant obese humans and rodents (Croce et al., 2007; Crunkhorn et al., 2007; Hammarstedt, Jansson, Wesslau, Yang, & Smith, 2003; Heinonen et al., 2017) . Liver-specific heterozygous PGC-1 mice (LPGC-1 ) display a ∼50% reduction in hepatic PGC-1 that mimics what has been measured in chronic obesity, and display greater susceptibility to hepatic steatosis with prolonged fasting or high-fat diets (Estall et al., 2009) . We sought to test the hypothesis that reduced hepatic PGC-1 expression would blunt the ability of FGF21 to mediate downstream metabolic effects in the liver. To test this hypothesis, we administered exogenous FGF21 for 4 weeks to mice with reduced hepatic PGC-1 expression (LPGC-1 ) or wild-type (WT) controls. We hypothesized that FGF21 dosing would significantly increase hepatic FAO, as well as the gene expression and protein content of important metabolic genes (CPT1 , PEPCK, G6Pase, TFAM and OXPHOS) in WT C57BL6 mice, and that these effects would be blunted in LPGC-1 +/− mice. We also examined whole-body metabolism via indirect calorimetry to determine whether whole-body substrate utilization and energy expenditure (EE) would track with expected hepatic changes.
New Findings
• What is the central question of this study? Does a reduction in hepatic peroxisome proliferatoractivated receptor coactivator-1 (PGC-1 ), which has been observed in an insulin-resistant obese state, impair the ability of fibroblast growth factor 21 (FGF21) to modulate metabolism?
• What is the main finding and its importance?
A deficit in hepatic PGC-1 does not compromise the ability of FGF21 to increase hepatic fatty acid oxidation; however, the effects of FGF21 to regulate whole-body metabolism (i.e. total and resting energy expenditure), as well as ambulatory activity, were altered when hepatic PGC-1 was reduced.
METHODS

Ethical approval
The animal protocol was approved by the Institutional Animal Care 
Animal protocol
The LPGC-1 mice were bred as previously described (Estall et al., 2009) . Briefly, female PGC-1 homozygote floxed mice on a C57Bl/6NJ background were purchased from Jackson Laboratory To insert osmotic minipumps, the animal was anaesthetized by inhalation of isoflurane. Initially, the animal was placed in an induction chamber and the flow was adjusted to 0.8-1.5 l min −1 , while the isoflurane vaporizer was set to 2.5-4%. For maintenance, a mask was used and flow adjusted to 400-800 ml min −1 . The animal was anaesthetized for 10-15 min, while body temperature was maintained with circulating water heating pads. Under general anaesthesia, a small insertion was made, the pump was implanted subcutaneously and the incision sutured close. The animal was continuously monitored during the surgery and until fully conscious and ambulatory. The animal was then monitored daily for 7 days for infection and for morbid or moribund signs.
Five mice from each group (four groups) were designated for FAO experiments. All other mice were used for indirect calorimetry studies, and mice from each type of experiment were pooled for tissue analysis (protein content and gene expression). Mice were individually housed in temperature-controlled animal quarters (21 • C) with an 06.00-18.00 h light phase and 18.00-06.00 h dark phase. All groups were provided with standard rodent chow for ad libitum feeding in new cages at the beginning of each week. After a 5 h fast, mice were anaesthetized with pentobarbital sodium (100 mg kg −1 ) and then exsanguinated by removal of the heart. Livers were excised and mitochondrial function was assessed by measuring palmitate oxidation, as well as protein content and gene expression of proteins important in FGF21 signalling and metabolic processes, as described the following subsections.
Tissue homogenization procedures
Livers were quickly excised from anaesthetized mice and either flash-frozen in liquid nitrogen or placed in ice-cold isolation buffer (mM: 220 mannitol, 70 sucrose, 10 Tris base and 1 EDTA; pH 7.4 adjusted by adding hydrochloric acid). Fresh liver homogenate was prepared as previously described (Rector et al., 2008) .
Body composition
Fat mass and lean mass were measured using an EchoMRI 4in1-1100 analyzer (EchoMRI, Houston, TX, USA).
Fatty acid oxidation
All FAO experiments were conducted as previously described Morris et al. 2016; Rector et al., 2008 was measured in whole-liver homogenate. The collection and measurement of 14 CO 2 palmitate oxidation allowed for the estimation of complete fatty acid oxidation (FAO to CO 2 ), and incomplete palmitate oxidation was assessed by measuring the 14 C in acid-soluble metabolites. In addition, etomoxir (CPT1 inhibitor) was also added to the reaction, and the resulting 14 CO 2 produced was collected as an estimate of extramitochondrial FAO.
Serum measurements
Serum glucose, insulin, adiponectin and lipids were determined using the Cobas c311 clinical chemistry analyser (Roche Diagnostics, Indianapolis, IN, USA). Serum ketones were measured using a commercially available -hydroxybutyrate Liquicolor kit (Stanbio, Boerne, TX, USA).
Western blotting
Western blot analyses were performed to determine protein content as performed by our group previously (Rector et al., 2008) 
Gene expression
Phosphoenolpyruvate carboxykinase, glucose 6-phosphatase (G6Pase), PGC-1 , CPT1 and mitochondrial transcription factor A (TFAM) mRNA expression were determined as previously described (Rector et al., 2010) . Results were quantified using the 2 −ΔΔC T technique relative to the cyclophilin-B (cycB) housekeeping gene.
Indirect calorimetry
Indirect calorimetry was carried out in a Promethion continuous indirect calorimetry unit from Sable Systems (Las Vegas, NV, USA) as reported previously (Park et al., 2017; Vieira-Potter et al., 2015) .
Some of the mice (n = 7-9) from each group were placed in indirect calorimetry chambers for a period of 4 days. The first 2 days provided an acclimation period, followed by analysis of data from the last 2 days in the chambers. In addition to measuring oxygen consumption and carbon dioxide production, the system also measured physical activity via beam breaks, and food and water intake and behaviour. All data from the indirect calorimetry chambers were analysed for 12 h circadian periods (12 h dark phase and 12 h light phase). Outcome data were calculated as reported previously (Morris et al., 2014; VieiraPotter et al., 2015) . Total EE (TEE) was calculated using analysis macros provided by the manufacturer (Sable Systems International), based on the Weir equations (Weir, 1949) . Resting EE (REE) was extrapolated from the average EE during a 30 min window with the lowest oxygen consumption and cage activity during each dark and light phase period. Non-resting EE (NREE) over a 24 h period was calculated as the difference between TEE and REE (Morris et al., 2014) . Body mass was used as a covariate for EE as reported previously (Morris et al., 2014) .
Statistics
Each outcome measure was examined in between five and 14 animals per group. Main effects of treatment (saline versus FGF21) and genotype (WT versus LPGC-1 ) were examined through a twoway ANOVA (IBM SPSS, version 24.0; SPSS, Chicago, IL, USA), and significant main effects (P ≤ 0.05) were followed with Fisher's LSD Abbreviations: FGF21, fibroblast growth factor 21; LPGC-1 , liver-specific PGC-1 heterozygous; PGC-1 , peroxisome proliferator-activated receptor coactivator-1 ; and WT, wild-type. Values are means ± SD (n = 4-5 per group). * Significant main effect of treatment (P ≤ 0.05). † Significant main effect of genotype (P ≤ 0.05).
TA B L E 1 Animal characteristics
‡ Interaction: WT-FGF21 is significantly different from WT-saline and LPGC-1 -FGF21 (P ≤ 0.05). § Interaction: LPGC-1 -FGF21 is significantly different from LPGC-1 -saline (P ≤ 0.05). Abbreviations: FGF21, fibroblast growth factor 21; FFA, free fatty acid; LPGC-1 , liver-specific PGC-1 heterozygous; n.a., not assessed; PGC-1 , peroxisome proliferator-activated receptor coactivator-1 ; TAG, triacylglycerol; and WT, wild-type. Values are means ± SD (n = 4-5). *Significant main effect of treatment (P ≤ 0.05). †Interaction: LPGC-1 -FGF21 is significantly different from WT-FGF21 and LPGC-1 -saline (P ≤ 0.05). ‡ Interaction: LPGC-1 -saline is significantly different from WT-saline (P ≤ 0.05).
TA B L E 2 Serum profile
post hoc comparisons. When a significant interaction explained a main effect(s), only the interaction was interpreted. Body mass was used as a covariate for EE. Values are reported as means ± SD, and a P value of ≤0.05 denotes a statistically significant difference.
RESULTS
Animal characteristics
The LPGC-1 mice had ∼50% lower hepatic PGC-1 gene expression compared with WT mice (P < 0.001; Table 1 ); however, hepatic PGC-1 expression was increased in both genotypes with 4 weeks of continuous FGF21 administration (P < 0.05; Table 1 ). Both WT and LPGC-1 mice experienced significant reductions in body weight (by ∼10%) and fat mass (by ∼50%) with FGF21 treatment (P < 0.05; Table 1 ). Absolute and relative food consumption was greater in FGF21-versus saline-treated mice of both genotypes; however, this effect was larger in WT mice (P < 0.05; Table 1 ). Despite the significant differences in food intake, there were no differences in lean body mass or the ratio of liver weight to body weight across groups (Table 1) .
Endogenous circulating FGF21 concentrations were not different between saline-treated WT and LPGC-1 mice (Table 2 ). FGF21 treatment significantly lowered insulin concentrations in WT (by 26%) and LPGC-1 (by 52%) animals (P = 0.016; Table 2 ). However, circulating glucose was not modulated by FGF21 in either genotype, although glucose tended (P = 0.093) to be greater in LPGC-1 versus WT mice. Furthermore, FGF21 increased ketone concentrations by ∼65% in both genotypes compared with saline-treated animals (P < 0.05; Table 2 ). Circulating adiponectin was significantly greater in saline-treated LPGC-1 mice compared with WT mice (P < 0.05, Table 2 ), and FGF21 treatment lowered adiponectin in LPGC-1 mice.
Additionally, although serum triglycerides did not differ between groups, FGF21 treatment lowered serum cholesterol (P = 0.014; Table 2 ) and tended to lower free fatty acids (P = 0.057, Table 2 ) in both genotypes.
Hepatic metabolism
Lower PGC-1 expression in the LPGC-1 mice resulted in a 30% reduction in complete FAO to CO 2 (P < 0.001; Figure 1a ). In addition, FGF21 treatment significantly increased complete FAO by 47% in WT mice and by 56% in LPGC-1 animals (P < 0.001; Figure 1a ).
Incomplete FAO, the products of which include shortened fatty acid chains produced by incomplete -oxidation, as well as ketones,
were increased by FGF21 treatment (P = 0.001; Figure 1b Values are means ± SD (n = 4-5). *Significant main effect of treatment (P ≤ 0.05). # Significant main effect of genotype (P ≤ 0.05) administration also increased total (complete + incomplete) FAO (P = 0.001; Figure 1c ). To examine extramitochondrial contributions to FAO, etomoxir, a CPT1 inhibitor, was used as described previously . LPGC-1 mice displayed blunted extramitochondrial FAO compared with WT (P = 0.018; Figure 1d ), but FGF21 administration increased extramitochondrial FAO in both genotypes (P = 0.02; Figure 1d ). FGF21-mediated increases in FAO resulted in similar reductions in hepatic triacylglycerol levels in both genotypes (P < 0.001; Figure 1e ). Further analysis showed that hepatic CPT1 gene expression and protein content, as well as pAMPK protein content, were not different between genotypes or between treatments (data not shown). Thus, despite LPGC-1 mice displaying reduced hepatic PGC-1 mRNA and complete FAO, there was no apparent defect in the capacity for chronic FGF21 treatment to increase FAO in LPGC-1 mice.
Whole-body metabolism
We also used indirect calorimetry to determine whether FGF21 administration impacted whole-body metabolism and spontaneous physical activity patterns in a different manner in LPGC-1 compared with WT mice. Total energy expenditure was not different during the light phase, but FGF21 administration led to significant increases in TEE in the dark phase (P = 0.009; Figure 2a) . This effect appears to be driven by FGF21-treated WT mice, as they displayed an 11% increase in TEE compared with a 4% increase in LPGC-1 mice. In fact, regardless of treatment, LPGC-1 mice experienced lower TEE when compared with WT mice (P = 0.046).
We next examined whether the differences in TEE were driven by REE or NREE. There were no differences in REE during the light phase, but FGF21 increased REE during the dark phase (P = 0.005; Figure 2b ), a main effect, again, probably driven by the WT mice, as 
Glucose metabolism
To investigate how reductions in hepatic PGC-1 and FGF21 administration impacted hepatic glucose production, we first measured hepatic glycogen content. LPGC-1 mice had higher hepatic glycogen content compared with WT mice regardless of treatment (saline versus FGF21; P < 0.05; Figure 3a) . However, when we assessed the gene expression of G6Pase, the rate-limiting enzyme for gluconeogenesis, and the gene expression and protein content of PEPCK, the enzyme responsible for the initial step of gluconeogenesis, we found no changes with FGF21 treatment or a reduction in LPGC-1 mice (Figure 3b-d) .
Mitochondrial biogenesis
Owing to the important role of PGC-1 in mitochondrial biogenesis and the potential of FGF21 to modulate mitochondrial function through PGC-1 , we assessed the hepatic protein content of the five complexes of the electron transport chain. The protein content of complexes II and V were each increased by ∼11% in WT mice and ∼7% in LPGC-1 mice with FGF21 administration (P ≤ 0.05; Figure 4a ).
However, hepatic Tfam gene expression, assessed because of its role as a mediator of mitochondrial biogenesis, did not differ among groups (Figure 4b ).
DISCUSSION
FGF21 is a powerful metabolic regulator that is increased during fasting or nutritionally compromised conditions (Galman et al., 2008; von Holstein-Rathlou et al., 2016) and is known to mediate metabolic processes including hepatic FAO, gluconeogenesis and ketogenesis (Potthoff et al., 2009 ). Owing to these features, it has also been examined as an agent to enhance EE and treat obesity (Ryden, 2009 ).
PGC-1 , a transcriptional coactivator known to regulate hepatic FAO and gluconeogenesis (Burgess et al., 2006; Morris et al., 2012) through gene transcription of proteins important to these metabolic processes, is also activated during times of fasting and exercise Experiments by Potthoff et al. (2009) demonstrated that FAO in fed FGF21 transgenic mice was similar to that observed in WT mice during fasting conditions when endogenous FGF21 was naturally elevated. Furthermore, Coskun et al. (2008) found that 2 weeks of FGF21 administration in diet induced obesity (DIO) mice lowered body weight (20%), adiposity and hepatic steatosis. These results demonstrate the effectiveness of FGF21 to promote leanness and reduce lipid storage. Previously, we showed that FGF21 knockout mice display suppressed hepatic FAO compared with WT mice . Our present results are in agreement with these previous studies and demonstrate that reductions in hepatic triacylglycerol tracked with a ∼50% increase in complete hepatic FAO in WT mice.
Moreover, FGF21 rescued hepatic fat oxidation in PGC-1 -deficient livers. Interestingly, LPGC-1 mice display greater hepatic steatosis compared with WT mice. Estall et al. (2009) demonstrated that liverspecific PGC-1 heterozygous mice had similar hepatic steatosis compared with WT mice and that it required an extended fast for PGC-1 heterozygous mice to accumulate greater lipid content in the liver. In the present study, mice were fasted for only 5 h before being killed; therefore, we were unable to observe this difference in phenotypes. The majority of FGF21 research examines the function of FGF21 in obesity, where the effects are more prominent, yet here we demonstrate that FGF21 is also capable of increasing FAO in lean mice.
As in many studies investigating FGF21 in the obese conditions (Owen et al., 2014; Xu et al., 2009) , we found that FGF21 lowers plasma insulin and cholesterol values. However, as opposed to studies using obese rodents, we did not observe lower circulating triglycerides (Owen et al., 2014; Xu et al., 2009) or increases in adiponectin (Guo et al., 2017) .
Complete FAO is the result of both mitochondrial and peroxisomal contributions. We specifically examined peroxisomal FAO by adding etomoxir, a CPT1 inhibitor, which blocks long-chain fatty acid entry into the mitochondria. We found that extramitochondrial FAO was elevated with FGF21 administration and was reduced, similar to that shown with complete FAO, in LPGC-1 mice. These data demonstrate that the actions of FGF21 and PGC-1 both impact mitochondrial and peroxisomal FAO. The present study also shows that FGF21 increases incomplete FAO, or the breakdown of long-chain fatty acids through -oxidation that are not processed through the tricarboxylic acid cycle but instead are siphoned off into primarily ketogenesis. These findings were supported by FGF21 treatment increasing circulating -hydroxybutyrate in both WT and LPGC-1 mice. As already stated, FGF21 is a key hormone for mediating fasting metabolic responses and has been shown previously to increase ketones (Potthoff et al., 2009) , an important fuel source during fasting (Reitman, 2007) .
Elevated hepatic FAO and an assumed increase in ATP production is largely used to support the energy-costly process of gluconeogenesis (Burgess et al., 2007; Williamson, Jakob, & Scholz, 1971) , which is upregulated during both fasting and endurance exercise. We did not observe any differences in gene expression of PEPCK and G6Pase, two important gluconeogenic enzymes in the LPGC-1 mice. Our findings differ from the conflicting reports of Fisher et al. (2011) and Potthoff et al. (2009) , who found that PEPCK and G6Pase gene expression is not (respectively) elevated in response to injections of FGF21 in PGC-1 null mice. The discrepancies in these findings from these three studies might be attributable to the dosage of FGF21, the duration of dosing (acute injections versus 4 weeks of treatment), the duration of fasting before the mice were killed, the timing of the end-point after exposure to FGF21, and the type of PGC-1 knockout model used.
In addition, gluconeogenesis was not directly measured in the present study; however, increased hepatic glycogen content in LPGC-1 mice suggests that the liver might have been compensating for reduced gluconeogenic capacity via an increased rate of glycogenolysis. Interestingly, circulating glucose concentrations tended to be higher in LPGC-1 mice, but were not reduced by FGF21 treatment. This is in contrast to previous studies in obese mice (Coskun et al., 2008; Kharitonenkov et al., 2005; Xu et al., 2009 ). In addition, FGF21 had no impact on in vivo substrate utilization, as no differences in respiratory exchange ratio were detected during indirect calorimetry studies.
However, the respiratory exchange ratio was not expected to change in response to treatment, because lean mice were studied and fed a lowfat chow diet.
PGC-1 plays an important role in mitochondrial biogenesis, and FGF21 has been shown to increase PGC-1 (Potthoff et al., 2009; Samms et al., 2015a) . Thus, we measured OXPHOS protein content to determine whether FGF21 modulated electron transport chain proteins and, if so, whether reduced PGC-1 abrogated this effect. Notably, FGF21 treatment increased the protein content of complexes II and V, which have previously been validated as markers of mitochondrial content (Larsen et al., 2012) ; changes that were not influenced by reduced hepatic PGC-1 . PGC-1 is involved in the transcription of subunits of the complexes of the electron transport chain in nuclear DNA and coactivates TFAM, which then translocates to mitochondrial DNA to transcribe additional subunits of the electron transport chain (Wredenberg et al., 2002; Wu et al., 1999) . Here, we found that hepatic Tfam mRNA expression was not altered by FGF21
administration despite increases in complex II and IV.
We found that FGF21 increased EE, confirming previous reports that FGF21 administration increases whole-body EE in DIO mice (Adams et al., 2012; Coskun et al., 2008; Samms et al., 2015b; Veniant et al. 2015; Xu et al., 2009) . Here, we also show that FGF21 administration increases TEE by enhancing REE more markedly in the WT, compared with LPGC-1 mice, during the dark phase. As in previous reports (Morris et al., 2014) , REE represented approximately 70-80% of TEE, while NREE represented 20-30% of TEE, and the dark-light cycle impacted these proportions as expected. Thus, the proportions of EE from NREE and REE were in the normal range.
Importantly, NREE, or the EE driven by non-resting conditions, was not increased by FGF21 treatment, which was an intriguing finding given that spontaneous activity measured by X + Y beam breaks was increased by approximately twofold in both the light and the dark periods. We show, for the first time, that FGF21, a fasting hormone, dramatically reduces EE per unit of movement, in a sense constraining the NREE as opposed to the REE.
Our finding that FGF21 increases ambulatory activity agrees with a previous study using DIO mice (Xu et al., 2009 ); however, changes in ambulatory activity are not always observed with administration of FGF21 (Adams et al., 2012; Coskun et al., 2008; Owen et al., 2014; Samms et al., 2015a; Sarruf et al., 2010; Veniant et al. 2015) . The reason for these conflicting findings is unknown, but complications associated with obesity and/or dosing might play a role. The type of indirect calorimetry system used might also be a contributing factor. The Promethion indirect calorimetry system is unique in that it continually measures metabolism in each cage for every second of the day. More importantly, in these experimental conditions increases in ambulatory activity occurred in lean chow-fed WT mice, but not in LPGC-1 mice. Previous research indicates that a deficit in hepatic PGC-1 may impact activity through gene transcription of proteins responsible for regulating the circadian rhythm, including
Clock, Bmal1, Cry1 and Cry2 (Liu, Li, Liu, Borjigin, & Lin, 2007) . Future studies are needed to delineate an exact mechanism by which PGC-1 deficiency impacts FGF21-mediated changes in spontaneous physical activity.
In conclusion, 4 weeks of continuous FGF21 administration robustly induced hepatic FAO in WT mice and in mice with reduced hepatic PGC-1 expression. Increased hepatic FAO tracked with reductions in hepatic steatosis, adiposity and body weight. These data suggest that FGF21 is able to compensate for reduced PGC-1 expression and rescue fatty acid metabolism. An additional new finding was that FGF21 increased TEE and REE to a greater extent in WT mice than in LPGC-1 mice. This finding suggests that reductions in hepatic PGC-1 impede the ability of FGF21 to modulate whole-body energy expenditure.
